Zanamivir (INN) (pronounced /zəˈnæmɨvɪr/) is a neuraminidase inhibitor used in the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza.
This text uses material from Wikipedia, licensed under CC BY-SA
Sorry, no news articles match your request
Science never stops. Get notified about trending stories.